Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.76
-0.05 (-0.30%)
At close: Apr 28, 2026, 4:00 PM EDT
16.99
+0.23 (1.37%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Theravance Biopharma Employees
Theravance Biopharma had 90 employees as of December 31, 2025. The number of employees decreased by 7 or -7.22% compared to the previous year.
Employees
90
Change (1Y)
-7
Growth (1Y)
-7.22%
Revenue / Employee
$1,194,044
Profits / Employee
$1,176,611
Market Cap
863.02M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| MeiraGTx Holdings | 403 |
| Kura Oncology | 260 |
| ARS Pharmaceuticals | 163 |
| Cullinan Therapeutics | 109 |
| Alto Neuroscience | 68 |
| Crescent Biopharma | 44 |
| Bright Minds Biosciences | 26 |
TBPH News
- 26 days ago - TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 5 weeks ago - Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
- 2 months ago - Theravance plans strategic review, including possible sale, after drug trial failure - Reuters
- 2 months ago - Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PRNewsWire
- 5 months ago - Theravance Biopharma Transcript: KOL Event - Transcripts
- 5 months ago - Theravance Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference - Transcripts
- 5 months ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire